Impression of Corda Campus, Hasselt. The former Philips site and current a local nucleus of transormation and innovation
10th EBF YSS (incl. 2nd EBF-University)
OPEN UP - Explore, Transform, Innovate
- Radisson Blu, Hasselt (Belgium)
-
10th YSS Symposium --- 16-17 May 2024
incl. 2th EBF University --- 15 May (13-19h)
Note:
For all the slide decks on this website, the presenter/affiliation continues holds the copyright. The EBF was provided approval to upload the slides as PDF on their conference website.
For slides presented on behalf of the EBF, the EBF vzw holds the copyright.
For all the slide decks on this website, the presenter/affiliation continues holds the copyright. The EBF was provided approval to upload the slides as PDF on their conference website.
For slides presented on behalf of the EBF, the EBF vzw holds the copyright.
The program itself can be viewed and downloaded by clicking here.
Program details of the EBF 9th YSS
| 2nd EBF University | ||
| Wednesday 15 May 2024 | ||
| 11:00 | Registration desk opens | |
| 13:00 | 18:30 | EBF University 2.0 (not released for publication) |
| We continue to build on the training material from the 1st EBF University (at the 9th YSS, 2023) (plenary – part 1) and expand into including hands-on round tables discussing real case studies in giving examples of how bioanalytical expert support (issue resolving, overall project support…) integrated into preclinical and clinical project teams adds value (round tables – part 2). The case studies will be moderated by (senior) experts from the EBF community or their network. Delegates will be assigned to the case studies considering their intertest and expertise. The case studies will be either ‘unassisted data mining’, moderated by a young scientist with expertise in the case study or moderated by a senior expert from our member companies | ||
| 13:00 | 13:18 | Introduction – project management in Drug R&D (Philip Timmerman, EBF) |
| 13:18 | 13:20 | The next generation of drugs (AI & ChatGPT) |
| 13:20 | 15:20 | Project support critical to drug R&D success |
| 13:20 | 13:40 | Drugability (Joao Pereira, Merck KGaA) |
| 13:40 | 14:00 | An introduction to Biomarkers (Peter Groenen, Curare) |
| 14:00 | 14:20 | An introduction to Biomarkers (Peter Groenen, Curare) |
| 14:20 | 14:30 | An introduction to Immunogenicity (Samuel Pine, Sanofi) |
| 14:30 | 15:00 | Project support: focus on clinical development (David Carlile, Roche) |
| 15:00 | 15:20 | Translational Sciences unravelled (Peter Groenen, Curare) |
| 15:20 | 16:00 | Q&A, coffee break and Case study preparation |
| 16:00 | 17:30 | Case studies |
| Case studies will be moderated by senior experts and/or scientist with direct involvement in the case study. We received 11 case studies. Each delegate will get the opportunity to contribute to the discussion of 3 case studies (taking into account their expertise). For this, we will assign the delegates to small teams with either Chromatography or LBA/CBA expertise. On Friday, we will present 8 out of 11 case studies to allow maximum exposure of the delegates to the issues presented in the case studies. | ||
| 16:00 | 16:40 | Case studies round 1 – 10min buffer time for logistics purposes |
| 16:50 | 17:30 | Case studies round 2 – 10min buffer time for logistics purposes |
| 17:40 | 18:20 | Case studies round 3 – 10min buffer time for logistics purposes |
| 18:20 | 18:30 | Close out remarks preparing for the 10th YSS and Adjourn |
| Free evening in Hasselt – no social event planned by the EBF YSS | ||
| EBF UNI Organisation | ||
| The 2nd EBF University program was prepared by the EBF with input from experts from our BioA community and adjacent disciplines (e.g.; nonclinical & clinical safety, DMPK, clinical PK, pharmacology, modelling & simulation and project management) | ||
| 10th YSS | ||
| Thursday 16 May 2024 | ||
| 08:00 | Registration desk opens | |
| 08:45 | 09:00 | Welcome and introduction to the 10th YSS |
| Philip Timmerman, EBF (not released for publication) | ||
| 09:00 | 10:40 | Session 1: The Science of Sustainability |
| Session chairs: Paul Heads, Orion Pharma and Friederike Vogt, BioAgilytix | ||
| 09:00 | 09:20 | Manca Spendal, Novo Nordisk |
| Microsampling in Toxicokinetic Studies: Reducing Animal Use and Enhancing Data Quality | ||
| 09:20 | 09:40 | Nadine Commandeur, Sanquin Diagnostic Services |
| Replacing radioactivity, reducing assay reagents and refining assay strategy – a glimpse into the new era of bioanalysis | ||
| 09:40 | 10:00 | Rose Nicol, AstraZeneca |
| Utilisation of VAMS to reduce sample volumes in pre-clinical toxicological studies in drug discovery | ||
| 10:00 | 10:20 | Tien Nguyen, Sanquin Diagnostic Services |
| Singlicate analysis strategy does work for antibody PK using ligand binding assays: the evidences from ELISA | ||
| 10:20 | 10:40 | Hanna de Baets, Ghent University (not released for publication) |
| Development and validation of an LC-MS/MS method for simultaneous determination of iohexol and creatinine for GFR estimation in cats using VAMS samples | ||
| 10:40 | 10:50 | Introduction to the 10th YSS Science Café |
| Science Café moderators: Fabian Gaertner, Nuvisan and Kyriel Pineault, UCB Pharma | ||
| 10:50 | 11:20 | Coffee break – DL for poster hanging |
| 11:20 | 12:20 | (Parallel) Session: New Technology LC-MS |
| Session chairs: Manuel Muenzer and Brian Dan, F. Hoffmann La Roche | ||
| 11:20 | 11:40 | Aline Vollmer, Saarland University (not released for publication) |
| Clinical toxicological analysis of toxins by means of antibody-based enrichment and liquid chromatography-high-resolution tandem mass spectrometry | ||
| 11:40 | 12:00 | Andrea di Ianni, Merck KGaA (not released for publication) |
| Unlocking the complexity of antibody-drug conjugated: a cutting-edge Liquid Chromatography High Resolution Mass Spectrometry approach for detecting conjugated payload metabolites | ||
| 12:00 | 12:20 | Frank Schalk, ICON (not released for publication) |
| Simultaneous isotyping and semi-quantitation of anti-drug antibodies to a monoclonal IgG1 biotherapeutic using hybrid-LC-MS/MS | ||
| 11:20 | 12:20 | (Parallel) Session: New Technology LBA |
| Session chairs: Rosie Penford, AstraZeneca and Sanam Ahmad, GSK | ||
| 11:20 | 11:40 | Lisa Wolter, AbbVie (not released for publication) |
| Development of Anti-AAV Antibody Assays to assess pre-existing immunity in study population | ||
| 11:40 | 12:00 | Jakob Alhede (replacing Michele Azzolini), AstraZeneca (not released for publication) |
| Fabs and tags, challenges and considerations when developing a ligand-binding immunoassay | ||
| 12:00 | 12:20 | Annabel Hood, Resolian (not released for publication) |
| Challenges in the development of a generic PK assay to measure the distribution of human biologics in mouse brain | ||
| 12:20 | 12:40 | Eva Hanckmann, Byondis |
| How to determine the exposure of masked ADCs: active or inactive drug? | ||
| 12:40 | 13:30 | Lunch – tables grouped to start Science Café discussions |
| 13:30 | 15:30 | 10th Science Café (Format: round table) |
| Science Café moderators: Fabian Gaertner, Nuvisan and Kyriel Pineault, UCB Pharma | ||
During the 10th EBF YSS conference, we will host the traditional Science Café, a roundtable discussion to promote dialogue on key topics and themes pertinent to the community. The topic for this year will be sustainability. We have divided the conversation into 3 key focus areas:
|
||
| 15:30 | 16:40 | Poster Pitch and posters discussion embedded in the coffee break |
| We will include a poster pitch session (i.e. 5-min short poster pitch by those signing up) in the first 30 minutes of the coffee break | ||
| 15:30 | 16:00 | We received six request to give a poster pitch (not released for publication) |
| Alina Zanga, Celerion Switzerland AG | ||
| The rollercoaster between free drug tolerance and target interference in the development of an antidrug antibody assay | ||
| Marie Thoelke, ADC Therapeutics | ||
| Streamlining Sample Analysis for Consistency and Efficiency – Tap into the App! | ||
| Katerina Koureta, Ardena Bioanalysis | ||
| Identification and analysis of bis(monoacylglycero)phosphates in varying matrices | ||
| Kateřina Augustynková, argenx | ||
| Generic immunogenicity assay for argenx drug molecules on Gyrolab® platform in non-clinical development | ||
| Janez Javornik, Charles River Laboratories | ||
| Development of a generic LC-MS/MS assay for the bioanalysis of 15-50-mer oligonucleotides in early pre-clinical studies. | ||
| Caroline Dumolyn, Sanofi | ||
| 3Rs: use of surrogate matrices in LBA PK assays | ||
| 16:00 | 16:40 | Coffee break and poster viewing |
| 16:40 | 17:40 | (Parallel) Session: When things go wrong in LC-MS/MS |
| Session chairs: Amelia Roberts, Quotient Sciences and Alexandra Bushby, Labcorp Drug Development | ||
| 16:40 | 17:00 | Aliz Széles, Semmelweis University; Research Centre for Natural Sciences and Toxi-Coop Toxicological Research Centre (all located in Budapest) (not released for publication) |
| Enabling toxicokinetic characterisation of 2,3-epoxypropyl isopropyl ether in the rat by substantial sensitivity improvement of the MS/MS detection | ||
| 17:00 | 17:20 | Jennifer Hawkins, Resolian |
| Take a Breath: The HILIC Hurdle in Validating Inhaled Cancer Probe Therapeutics | ||
| 17:20 | 17:40 | Sebastian Zimmermann, Nuvisan |
| Unveiling the significance of temperature control for large molecule LC-MS bioanalysis | ||
| 16:40 | 18:00 | (Parallel) Session: When things go wrong in LBA |
| Session chairs: Alina Zanga, Celerion and Caroline Dumolyn, Sanofi | ||
| 16:40 | 17:00 | Richie Lofthouse, GSK |
| Everything, Everywhere, All at Once: Troubleshooting lot-lot variability and analyte stability issues on the ELLA platform | ||
| 17:00 | 17:20 | Lisanne Dijk, Sanquin Diagnostic Services |
| How to deal with pre-existing antibodies and interference in immunoassays | ||
| 17:20 | 17:40 | Anna Kucher, Ardena |
| Navigating Anomalies: Optimization of a peptide Anti-Drug Antibody assay | ||
| 17:40 | 18:00 | Chiel van Geffen, Sanquin Diagnostic Services (not released for publication) |
| Matrix effects in a sC5b-9 ELISA | ||
| 19:30 | 22:30 | 10th YSS Conference Dinner |
| Friday 17 May 2024 | ||
| 09:00 | 10:10 | Session: Biomarkers |
| Session chairs: Sonya Belle, Charles River Laboratories and Fabian Gaertner, Nuvisan | ||
| 09:00 | 09:10 | Philip Timmerman, EBF |
| Introduction to Biomarkers – CoU | ||
| 09:10 | 09:30 | Liesl Heughebaert, Ghent University (not released for publication) |
| Assessment of the status of thiamine and the alcohol biomarker phosphatidylethanol 16:0/18:1 in the Belgian adult population using volumetric absorptive microsampling: results from the Belgian Food Consumption Survey | ||
| 09:30 | 09:50 | Alex Mulvanny, MEU |
| Sputum Supernatant Biomarker Assay Validation | ||
| 09:50 | 10:10 | Manca Spendal, Novo Nordisk (not released for publication) |
| Cross-functional collaboration and agreement on context of use – case study | ||
| 10:10 | 11:00 | Discussions @ posters during coffee break |
| 11:00 | 12:00 | (Parallel) – Case studies from EBF University unraveled (not released for publication) |
| Session chairs: Claire Szuster, Resolian and Paul Heads, Orion Pharma | ||
| 11:00 | 11:15 | Feedback from the Quotient Sciences case study discussed a the EBF University |
| Amelia Roberts, Quotient Sciences | ||
| 11:15 | 11:30 | Feedback from the Novo Nordisk case study discussed a the EBF University |
| Manca Spendal, Novo Nordisk | ||
| 11:30 | 11:45 | Feedback from the GSK case study discussed a the EBF University |
| Sanam Ahmad, GSK | ||
| 11:45 | 12:00 | Feedback from the ICON case study 02a discussed a the EBF University |
| Sara Russo, ICON | ||
| 11:00 | 12:00 | (Parallel) – Case studies from EBF University unraveled (not released for publication) |
| Session chairs: Alex Bushby, Labcorp Drug Development and Rosie Penford, AstraZeneca | ||
| 11:00 | 11:15 | Feedback from the Byondis case study 01 discussed a the EBF University |
| Eva Hanckmann, Byondis | ||
| 11:15 | 11:30 | Feedback from the Sanofi case study discussed a the EBF University |
| Caroline Dumolyn, Sanofi | ||
| 11:30 | 11:45 | Feedback from the ICON case study 01 discussed a the EBF University |
| Frank Schalk, ICON | ||
| 11:45 | 12:00 | Feedback from the Genmab case study discussed a the EBF University |
| Federica Calderaro, Genmab | ||
| 12:00 | 13:00 | Lunch break |
| 13:00 | 14:20 | Session: And now for something different |
| Session chairs: Kyriel Pineault, UCB Pharma and Simon Wellenberg, Saarland University | ||
| 13:00 | 13:20 | Jakob Alhede, AstraZeneca (not released for publication) |
| Branched DNA – “To be a GLP assay or not to be? That is the question.” | ||
| 13:20 | 13:40 | Manon Chevallot-Beroux, Sanquin Diagnostic Services |
| Monocyte Activation Test (MAT); adaptable to serve any product | ||
| 13:40 | 14:00 | Anna Marzeda, AstraZeneca (not released for publication) |
| Sense and Sensibility, or how to deliver timely and high-quality bioanalytical support of disruptive biology drug products (and stay sane) | ||
| 14:00 | 14:20 | Nina Hilbert, AbbVie (not released for publication) |
| Evaluation of ADC brain delivery in rodents via cerebrospinal fluid administration leveraging in vivo cOFM | ||
| 14:20 | 15:00 | Discussions @ posters during coffee break |
| 15:00 | 16:20 | (Parallel) Session: LC-MS new Technologies |
| Session chairs: Claire Szuster, Resolian and Kevin Vandenbroucke Ghent University | ||
| 15:00 | 15:20 | Marie Reille-Seroussi, Sanofi |
| Automated immunocapture of biotherapeutics for LC-MS analysis: Comparison of the AssayMAP Bravo and KingFisherTM robotic platforms. | ||
| 15:20 | 15:40 | Elisa Milandri, Bologna University (not released for publication) |
| Volumetric absorptive microsampling and fully-automated sample treatment in a patient-centric study aimed at modern therapeutic drug monitoring | ||
| 15:40 | 16:00 | Dorian van Kuijk, Byondis |
| The quantification of intracellular phosphonate levels by LC/MS | ||
| 16:00 | 16:20 | Daniel Diaz, Novo Nordisk |
| Sample preparation strategies for low concentration biomarker assays in human plasma | ||
| 15:00 | 16:20 | (Parallel) Session: And now for something completely different |
| Session chairs: Eva Hanckmann, Byondis and Sara Russo, ICON | ||
| 15:00 | 15:20 | Klara Szydlo, BioAgilytix |
| Application of the MSD S-PLEX platform for measuring PK of low amounts of an RNA-LNP translational bispecific antibody | ||
| 15:20 | 15:40 | Laura Boffel, Ghent University (not released for publication) |
| Self-sampling by adolescents at home: assessment of the feasibility to collect qualitative samples by unexperienced individuals | ||
| 15:40 | 16:00 | Mohammed Binyameen Khan, Labcorp |
| Challenges Of Developing an Optimized Drug Tolerant Neutralising Antibody Assay, with Cost, Complexity and Time Efficiency in Mind | ||
| 16:00 | 16:20 | Roberta Di Lecce, University of Bologna (not released for publication) |
| The role of dry and wet microsampling in the analytical workflow for the determination of sports doping agents | ||
| 10 min. logistic break | ||
| 16:30 | 16:45 | Announcement 2024 YSS Best Poster Winner |
| 16:45 | 17:00 | Evaluation of the EBF University v2.0 + Closing Remarks and Adjourn |
| Patrons of the 10th YSS: We thank our patrons of the 10th YSS for their support: BioAgilytix, Boehringer Ingelheim, ICON and Merck KGaA | ||
| Meeting Organisation (OC): Eva Hanckmann, Byondis; Kevin Vandenbroucke Ghent University; Caroline Dumolyn, Sanofi; Friederike Vogt, BioAgilytix; Simon Wellenberg and Aline Vollmer; Saarland University; Kyriel Pineault, UCB Pharma; Lisa Wolter, Abbvie; Paul Heads, Orion Pharma; Marie Sole Giordano, Swiss Bioquant; Fabian Gaertner, Nuvisan; Claire Szuster, Resolian; Manca Spendal, NovoNordisk; Amelia Roberts, Quotient Sciences; Harriet Thomas/Sanam Ahmad (until January 2024/from January 2024), GSK; Alina Zanga, Celerion; Jayshree Maher/Rosie Penford, AstraZeneca (until January 2024/from February 2024); Mariana Carneiro Da Cunha, Intertek; Sara Russo, ICON; Marie Reille-Seroussi, Sanofi; Andrea Di Ianni, Merck KGaA; Manuel Muenzer and Brian Dan, F. Hoffmann La Roche, Alexandra Bushby, Labcorp Drug Development; Elisa Milandri, University of Bologna and Sonya Belle, Charles River Laboratories, Jayshree Maher, Invox Pharma (from March 2024). | ||
| Meeting management: Philip Timmerman (EBF) | ||
The symposium and EBF UNI are organised as a non-profit event by the EBF vzw.
The organisation is independent from the EBF member companies.
